TERT and neoplasm: Two somatic mutations, chr5:1,295,228C > T and chr5:1,295,250C > T (termed here as C228T and C250T, respectively), in the promoter of the gene for telomerase reverse transcriptase (TERT) were found to be associated with poor clinicopathological outcomes of PTC, including aggressive tumor behaviors and increased disease recurrences, making them potentially useful new prognostic molecular makers for PTC [18–22].